Has Jessica Jameson, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,123,852 in general payments to Jessica Jameson, MD across 729 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jessica Jameson, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jessica Jameson, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jessica Jameson, MD

Pain Medicine · Post Falls, IDNPI 1669573929

Payments from drug & device makers

$1,123,852in general payments, 2019–2025

Across 729 payments — averaging $1541.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Nevro Corp.$421K
Boston Scientific$336K
SPR Therapeutics, Inc$118K
Saluda Medical Americas, Inc.$92K
Abbott$87K
Stimwave Technologies Incorporated$41K
plus $30K from 20 others

$355in research payments, 2019–2025

Across 5 payments — averaging $70.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Nevro Corp.$227
Saluda Medical Americas, Inc.$128

What the payments were for

Consulting fees$69,16927%
Speaking & faculty fees$135,97052%
Travel & lodging$36,86214%
Food & beverage$15,3136%
Gifts$3040%
Entertainment$3,3481%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Nevro Corp.	223	$420,979
Boston Scientific	157	$336,203
SPR Therapeutics, Inc	25	$117,952
Saluda Medical Americas, Inc.	50	$91,628
Abbott	111	$86,510
Stimwave Technologies Incorporated	61	$40,873
Vertiflex, Inc.	14	$14,221
Vertos Medical, Inc.	12	$8,373
Medtronic(2 entities)	39	$2,046
Globus Medical	2	$1,527
Si-bone, Inc.	6	$1,471
Sawtooth Surgical Solutions Inc	3	$894
Relievant Medsystems, Inc.	6	$329
Arthrex	3	$218
Radius Health, Inc.	1	$125
Stryker	2	$119
Johnson & Johnson	2	$68
Avanos Medical	1	$57
Nalu Medical, Inc.	2	$57
MML US, Inc.	1	$46
Amgen	2	$37
Painteq LLC	2	$36
Averitas Pharma Inc.	1	$28
Osteocentric Technologies, Inc.	1	$27
Bioventus LLC	1	$18
Merit Medical Systems Inc	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Senza Spinal Cord Stimulation System$73,532
Omnia$29,603
SPECTRA WAVEWRITER$15,499
SPRINT PNS System$11,085
SUPERION$10,200
Senza$9,087
Superion ISS$8,381
mild Device Kit$8,205
Intracept$7,500
Evoke SCS$6,169
Neuromodulation Dspsbls and Accs$3,426
Superion Indirect Decompression System$1,750
iFuse Implant$1,251
Proclaim Family of SCS IPGs$1,182
GENERAL - THERAPIES$1,165
INTELLIS$887
Prodigy Family of SCS IPGs$575
PROCLAIM$450
Proclaim IPG$435
Neuromodulation-Research Only$426

How this compares

$1,123,852 in reported general payments places this provider in the 95th percentile of 32 pain medicine providers in Idaho.

See all pain medicine providers in Idaho →

Medicare billing

Part B allowed, 2024

$154,706

Medicare patients

544

Services billed

1,443

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Buprenorphine	12	$2,154
Fentanyl	12	$909
Celecoxib	19	$891
Gabapentin	34	$525
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	23	$404
Pregabalin	16	$386
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	12	$193
Oxycodone Hcl	14	$187
Methylprednisolone	19	$84
Tizanidine Hcl	12	$76
Triazolam	27	$32

Paid to pharmacies, not to this prescriber.